Abstract
As drug discovery and development in Neuroscience push beyond symptom management to disease modification, neuroimaging becomes a key area of translational research that enables measurements of the presence of drugs and downstream physiological consequences of drug action within the living brain. As such, neuroimaging can be used to help optimize decision-making processes throughout the various phases of drug development. Positron Emission Tomography (PET) is a functional imaging technique that allows the quantification and visualization of biochemical processes, by monitoring the time dependent distribution of molecules labelled with short-lived positron-emitting isotopes. This review focuses on the application of PET to support CNS drug development, particularly in the early clinical phases, by allowing us to measure tissue exposure, target engagement, and pharmacological activity. We will also discuss the application of PET imaging as tools to image the pathological hallmarks of disease and evaluate the potential disease-modifying effect of candidate drugs in slowing disease progression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study. (2017). https://ClinicalTrials.gov/show/NCT02850146.
Abanades, S., van der Aart, J., Barletta, J. A., Marzano, C., Searle, G. E., Salinas, C. A., et al. (2011). Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. Journal of Cerebral Blood Flow and Metabolism, 31(3), 944–952. https://doi.org/10.1038/jcbfm.2010.175.
Adams, J. R., van Netten, H., Schulzer, M., Mak, E., McKenzie, J., Strongosky, A., et al. (2005). PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain, 128(Pt 12), 2777–2785. https://doi.org/10.1093/brain/awh607.
Antonini, A., Moresco, R. M., Gobbo, C., De Notaris, R., Panzacchi, A., Barone, P., et al. (2001). The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurological Sciences, 22(1), 47–48.
Banks, W. A. (2004). Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain? Current Pharmaceutical Design, 10(12), 1365–1370.
Batla, A., Erro, R., Stamelou, M., Schneider, S. A., Schwingenschuh, P., Ganos, C., et al. (2014). Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Movement Disorders, 29(14), 1820–1825. https://doi.org/10.1002/mds.26018.
Bauer, M., Langer, O., Dal-Bianco, P., Karch, R., Brunner, M., Abrahim, A., et al. (2006). A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clinical Pharmacology and Therapeutics, 80(3), 216–227. https://doi.org/10.1016/j.clpt.2006.05.007.
Begley, D. J. (2004). Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacology & Therapeutics, 104(1), 29–45. https://doi.org/10.1016/j.pharmthera.2004.08.001.
Bergstrom, M., Grahnen, A., & Langstrom, B. (2003). Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. European Journal of Clinical Pharmacology, 59(5–6), 357–366. https://doi.org/10.1007/s00228-003-0643-x.
Braak, H., & Braak, E. (2000). Pathoanatomy of Parkinson's disease. Journal of Neurology, 247(Suppl 2), II3–I10. https://doi.org/10.1007/PL00007758.
Broadwell, R. D. (1989). Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal. Acta Neuropathologica, 79(2), 117–128.
Chen, K., Langbaum, J. B., Fleisher, A. S., Ayutyanont, N., Reschke, C., Lee, W., et al. (2010). Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's disease neuroimaging initiative. Neuroimage, 51(2), 654–664. https://doi.org/10.1016/j.neuroimage.2010.02.064.
Christian, B. T., Livni, E., Babich, J. W., Alpert, N. M., Dischino, D. D., Ruediger, E., et al. (1996). Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. The Journal of Pharmacology and Experimental Therapeutics, 279(1), 325–331.
de la Fuente-Fernandez, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., et al. (2011). Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology, 69(5), 803–810. https://doi.org/10.1002/ana.22284.
Deo, A. K., Theil, F. P., & Nicolas, J. M. (2013). Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Molecular Pharmaceutics, 10(5), 1581–1595. https://doi.org/10.1021/mp300570z.
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. The New England Journal of Medicine, 370(4), 311–321. https://doi.org/10.1056/NEJMoa1312889.
Eckert, T., Barnes, A., Dhawan, V., Frucht, S., Gordon, M. F., Feigin, A. S., et al. (2005). FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage, 26(3), 912–921. https://doi.org/10.1016/j.neuroimage.2005.03.012.
Eckert, T., Van Laere, K., Tang, C., Lewis, D. E., Edwards, C., Santens, P., et al. (2007). Quantification of Parkinson's disease-related network expression with ECD SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 34(4), 496–501. https://doi.org/10.1007/s00259-006-0261-9.
Feigin, A., Fukuda, M., Dhawan, V., Przedborski, S., Jackson-Lewis, V., Mentis, M. J., et al. (2001). Metabolic correlates of levodopa response in Parkinson's disease. Neurology, 57(11), 2083–2088.
Gunn, R. N., Gunn, S. R., & Cunningham, V. J. (2001). Positron emission tomography compartmental models. Journal of Cerebral Blood Flow and Metabolism, 21(6), 635–652. https://doi.org/10.1097/00004647-200106000-00002.
Gunn, R. N., Summerfield, S. G., Salinas, C. A., Read, K. D., Guo, Q., Searle, G. E., et al. (2012). Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. Journal of Cerebral Blood Flow and Metabolism, 32(5), 874–883. https://doi.org/10.1038/jcbfm.2012.1.
Hilker, R., Voges, J., Weisenbach, S., Kalbe, E., Burghaus, L., Ghaemi, M., et al. (2004). Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. Journal of Cerebral Blood Flow and Metabolism, 24(1), 7–16. https://doi.org/10.1097/01.WCB.0000092831.44769.09.
Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A. H., et al. (2005). Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Archives of Neurology, 62(3), 378–382. https://doi.org/10.1001/archneur.62.3.378.
Honer, M., Gobbi, L., Martarello, L., & Comley, R. A. (2014). Radioligand development for molecular imaging of the central nervous system with positron emission tomography. Drug Discovery Today, 19(12), 1936–1944. https://doi.org/10.1016/j.drudis.2014.08.012.
Huiban, M., Coello, C., Wu, K., Xu, Y., Lewis, Y., Brown, A. P., et al. (2017). Investigation of the brain biodistribution of the lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor [(18)F]GSK2647544 in healthy male subjects. Molecular Imaging and Biology, 19(1), 153–161. https://doi.org/10.1007/s11307-016-0982-5.
ICH (2009). Guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. In I. T. I. C. o. H. o. T. R. f. R. o. P. f. H. U. (ICH) (Ed.), ICH M3 (R2).
ICRP (1992). Radiological protection in biomedical research. CRP Publication 62. Ann., 22(3).
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism, 27(9), 1533–1539. https://doi.org/10.1038/sj.jcbfm.9600493.
Kaasinen, V., & Vahlberg, T. (2017). Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies. Annals of Neurology, 82(6), 873–882. https://doi.org/10.1002/ana.25103.
Khan, N. L., Valente, E. M., Bentivoglio, A. R., Wood, N. W., Albanese, A., Brooks, D. J., et al. (2002). Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Annals of Neurology, 52(6), 849–853. https://doi.org/10.1002/ana.10417.
Khan, N. L., Scherfler, C., Graham, E., Bhatia, K. P., Quinn, N., Lees, A. J., et al. (2005). Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology, 64(1), 134–136. https://doi.org/10.1212/01.WNL.0000148725.48740.6D.
Li, W., Lao-Kaim, N. P., Roussakis, A. A., Martin-Bastida, A., Valle-Guzman, N., Paul, G., et al. (2018). (11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 33(1), 117–127. https://doi.org/10.1002/mds.27183.
Lin, T. P., Carbon, M., Tang, C., Mogilner, A. Y., Sterio, D., Beric, A., et al. (2008). Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain, 131(Pt 5), 1373–1380. https://doi.org/10.1093/brain/awn031.
Marshall, V. L., Patterson, J., Hadley, D. M., Grosset, K. A., & Grosset, D. G. (2006). Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nuclear Medicine Communications, 27(12), 933–937. https://doi.org/10.1097/01.mnm.0000243374.11260.5b.
Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C. S., et al. (2009). Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain, 132(Pt 11), 2970–2979. https://doi.org/10.1093/brain/awp209.
National Academies of Sciences (2017). In Therapeutic development in the absence of predictive animal models of nervous system disorders: Proceedings of a Workshop (The National Academies Collection: Reports funded by National Institutes of Health). Washington (DC).
Neves, V., Aires-da-Silva, F., Corte-Real, S., & Castanho, M. A. R. B. (2016). Antibody approaches to treat brain diseases. Trends in Biotechnology, 34(1), 36–48.
Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D. J., et al. (2012). Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Archives of Neurology, 69(2), 198–207. https://doi.org/10.1001/archneurol.2011.1538.
Piccini, P., Burn, D. J., Ceravolo, R., Maraganore, D., & Brooks, D. J. (1999). The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Annals of Neurology, 45(5), 577–582.
Plenge, R. M. (2016). Disciplined approach to drug discovery and early development. Science Translational Medicine, 8(349), 349ps315. https://doi.org/10.1126/scitranslmed.aaf2608.
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews. Drug Discovery, 11(3), 191–200. https://doi.org/10.1038/nrd3681.
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 14(1), 105. https://doi.org/10.1186/s12967-016-0838-4.
Schulz-Schaeffer, W. J. (2010). The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathologica, 120(2), 131–143. https://doi.org/10.1007/s00401-010-0711-0.
Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P. H., Williams, L., Maier, M., et al. (2016). The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature, 537(7618), 50–56. https://doi.org/10.1038/nature19323.
Simuni, T., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., Jennings, D., et al. (2018). Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Movement Disorders. https://doi.org/10.1002/mds.27361.
Snow, B. J., Tooyama, I., McGeer, E. G., Yamada, T., Calne, D. B., Takahashi, H., et al. (1993). Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Annals of Neurology, 34(3), 324–330. https://doi.org/10.1002/ana.410340304.
Tang, C. C., Poston, K. L., Eckert, T., Feigin, A., Frucht, S., Gudesblatt, M., et al. (2010). Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurology, 9(2), 149–158. https://doi.org/10.1016/S1474-4422(10)70002-8.
Tinaz, S., Chow, C., Kuo, P. H., Krupinski, E. A., Blumenfeld, H., Louis, E. D., et al. (2018). Semiquantitative analysis of dopamine transporter scans in patients with Parkinson disease. Clinical Nuclear Medicine, 43(1), e1–e7. https://doi.org/10.1097/RLU.0000000000001885.
Tolmachev, V., Orlova, A., & Andersson, K. (2014). Methods for radiolabelling of monoclonal antibodies. Methods in Molecular Biology, 1060, 309–330. https://doi.org/10.1007/978-1-62703-586-6_16.
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., et al. (2016). Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's Research & Therapy, 8(1), 18. https://doi.org/10.1186/s13195-016-0189-7.
Whone, A. L., Moore, R. Y., Piccini, P. P., & Brooks, D. J. (2003). Plasticity of the nigropallidal pathway in Parkinson's disease. Annals of Neurology, 53(2), 206–213. https://doi.org/10.1002/ana.10427.
Zubal, I. G., Early, M., Yuan, O., Jennings, D., Marek, K., & Seibyl, J. P. (2007). Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. Journal of Nuclear Medicine, 48(6), 857–864. https://doi.org/10.2967/jnumed.106.037432.
Acknowledgements
The opportunity to write this review article arose from the Hadassah conference, which was funded by the Foundation for the National Institute of Health (NIH R21DA040852).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval and informed consent
This is a review article and therefore does not contain any new data from studies with human participants or animals performed by any of the authors.
Electronic supplementary material
ESM 1
(DOCX 13 kb)
Rights and permissions
About this article
Cite this article
Suridjan, I., Comley, R.A. & Rabiner, E.A. The application of positron emission tomography (PET) imaging in CNS drug development. Brain Imaging and Behavior 13, 354–365 (2019). https://doi.org/10.1007/s11682-018-9967-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11682-018-9967-0